Last reviewed · How we verify
Parecoxib Sodium/Valdecoxib
Parecoxib Sodium/Valdecoxib is a Selective COX-2 inhibitor (coxib) Small molecule drug developed by Pfizer. It is currently FDA-approved for Acute postoperative pain, Rheumatoid arthritis, Osteoarthritis.
Parecoxib sodium is a selective COX-2 inhibitor that reduces prostaglandin production to provide anti-inflammatory and analgesic effects.
Parecoxib sodium is a selective COX-2 inhibitor that reduces prostaglandin production to provide anti-inflammatory and analgesic effects. Used for Acute postoperative pain, Rheumatoid arthritis, Osteoarthritis.
At a glance
| Generic name | Parecoxib Sodium/Valdecoxib |
|---|---|
| Sponsor | Pfizer |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Parecoxib is the intravenous prodrug of valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor. By selectively blocking COX-2, it reduces the production of pro-inflammatory prostaglandins while sparing COX-1-mediated protective effects in the gastrointestinal tract and platelets. This selectivity provides pain relief and anti-inflammatory benefits with a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs.
Approved indications
- Acute postoperative pain
- Rheumatoid arthritis
- Osteoarthritis
Common side effects
- Hypertension
- Edema
- Dyspepsia
- Headache
- Cardiovascular events (thromboembolic)
Key clinical trials
- Effect of Intravenous Dynastat on Postoperative Sore Throat (PHASE2)
- Effect Study of Parecoxib to Treat Emergence Delirium and Postoperative Pain (PHASE4)
- A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery (PHASE3)
- A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Parecoxib Sodium/Valdecoxib CI brief — competitive landscape report
- Parecoxib Sodium/Valdecoxib updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Parecoxib Sodium/Valdecoxib
What is Parecoxib Sodium/Valdecoxib?
How does Parecoxib Sodium/Valdecoxib work?
What is Parecoxib Sodium/Valdecoxib used for?
Who makes Parecoxib Sodium/Valdecoxib?
What drug class is Parecoxib Sodium/Valdecoxib in?
What development phase is Parecoxib Sodium/Valdecoxib in?
What are the side effects of Parecoxib Sodium/Valdecoxib?
What does Parecoxib Sodium/Valdecoxib target?
Related
- Drug class: All Selective COX-2 inhibitor (coxib) drugs
- Target: All drugs targeting COX-2 (Cyclooxygenase-2)
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Pain Management / Rheumatology
- Indication: Drugs for Acute postoperative pain
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Osteoarthritis